---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-083386"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:50:16.254810+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lexeo positive Phase 1/2 data for LX2006 in FA cardio: LVMI -11.4% at 12mo, safe

## Summary
- Mean LVMI reduction 11.4% at 12 months and 18.3% at 18 months in patients with elevated baseline LVMI.
- 75% of elevated-baseline patients achieved >10% LVMI reduction at 12 months.
- hsTnI, a myocardial injury biomarker, reduced 53.3% on average at 12 months (n=5).
- Frataxin expression increased post-treatment in all evaluable biopsies; no treatment-related SAEs.
- Cohort 3 dosing started (1.2x10^12 vg/kg); DSMB endorsed progression; 13 total participants dosed.

## SEC filing metadata
- accession: 0000950170-24-083386
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024083386/0000950170-24-083386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024083386/lxeo-20240715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-083386
- JSON: https://secwatch.observer/filing/0000950170-24-083386.json
- Plain text: https://secwatch.observer/filing/0000950170-24-083386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.